1. Home
  2. VKTX vs TGNA Comparison

VKTX vs TGNA Comparison

Compare VKTX & TGNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VKTX
  • TGNA
  • Stock Information
  • Founded
  • VKTX 2012
  • TGNA 1906
  • Country
  • VKTX United States
  • TGNA United States
  • Employees
  • VKTX N/A
  • TGNA N/A
  • Industry
  • VKTX Biotechnology: Pharmaceutical Preparations
  • TGNA Broadcasting
  • Sector
  • VKTX Health Care
  • TGNA Industrials
  • Exchange
  • VKTX Nasdaq
  • TGNA Nasdaq
  • Market Cap
  • VKTX 3.5B
  • TGNA 3.4B
  • IPO Year
  • VKTX 2015
  • TGNA N/A
  • Fundamental
  • Price
  • VKTX $23.09
  • TGNA $20.95
  • Analyst Decision
  • VKTX Strong Buy
  • TGNA Buy
  • Analyst Count
  • VKTX 12
  • TGNA 4
  • Target Price
  • VKTX $87.50
  • TGNA $20.00
  • AVG Volume (30 Days)
  • VKTX 6.8M
  • TGNA 3.2M
  • Earning Date
  • VKTX 10-22-2025
  • TGNA 11-06-2025
  • Dividend Yield
  • VKTX N/A
  • TGNA 2.38%
  • EPS Growth
  • VKTX N/A
  • TGNA 15.85
  • EPS
  • VKTX N/A
  • TGNA 2.77
  • Revenue
  • VKTX N/A
  • TGNA $3,032,450,000.00
  • Revenue This Year
  • VKTX N/A
  • TGNA N/A
  • Revenue Next Year
  • VKTX N/A
  • TGNA $11.48
  • P/E Ratio
  • VKTX N/A
  • TGNA $7.58
  • Revenue Growth
  • VKTX N/A
  • TGNA 5.89
  • 52 Week Low
  • VKTX $18.92
  • TGNA $14.26
  • 52 Week High
  • VKTX $81.73
  • TGNA $21.35
  • Technical
  • Relative Strength Index (RSI)
  • VKTX 32.25
  • TGNA 62.94
  • Support Level
  • VKTX $24.82
  • TGNA $20.81
  • Resistance Level
  • VKTX $26.50
  • TGNA $21.13
  • Average True Range (ATR)
  • VKTX 1.18
  • TGNA 0.14
  • MACD
  • VKTX -0.20
  • TGNA -0.16
  • Stochastic Oscillator
  • VKTX 2.47
  • TGNA 31.82

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

About TGNA TEGNA Inc

Tegna Inc is a media company with a portfolio of broadcast stations and digital sites. The firm has television stations and radio stations in approximately U.S. markets. The company owns multicast networks of True Crime Network, Twist, and Quest. Each television station also has a robust digital presence across online, mobile, connected television, and social platforms, reaching consumers on all devices and platforms used to consume news content. It generates key revenue from advertising and marketing services, subscriptions, political advertising, and other services.

Share on Social Networks: